|
Synonyms: KH902 | KH903 | Lumitin® (China)
conbercept is an approved drug
Compound class:
Peptide
Comment: Conbercept is a VEGF ligand trap. It comprises VEGF binding domains from VEGF receptors 1 and 2 including VEGFR-2 domain 4, fused to a human IgG Fc domain. Conbercept binds to and neutralizes all VEGF isoforms [4].
|
| No information available. |
Summary of Clinical Use ![]() |
| Conbercept has been approved for clinical use in China since 2013 [1]. Intravitreally administered conbercept is used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02194634 | Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing) | Phase 3 Interventional | Chengdu Kanghong Biotech Co., Ltd. | 2 | |
| NCT03108352 | Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion | Phase 3 Interventional | Chengdu Kanghong Biotech Co., Ltd. | 3 | |